Report from the first Tanzania Liver Cancer Conference: a call for action to unite in the fight against liver cancer in Sub-Saharan Africa, 17–18 March 2023, Dar es Salaam, Tanzania
暂无分享,去创建一个
N. Brand | E. Mbuguje | A. Mwanga | Charles K. Pallangyo | J. Alswang | A. Swallow | Deogratius Beda Mwanakulya | Seif Wibonela | Eva Uiso | William Kitua | Saleh Pazi | Deogratius Mwanakulya
[1] G. Dusheiko,et al. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. , 2022, The lancet. Gastroenterology & hepatology.
[2] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[3] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[4] Emanuel P. Lyimo,et al. Cancer Mortality Patterns in Tanzania: A Retrospective Hospital-Based Study, 2006-2015 , 2020, JCO global oncology.
[5] Gregory J. Gores,et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] A. Rademaker,et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.
[8] P. Chalya,et al. Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting , 2014, World Journal of Surgical Oncology.
[9] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.